Bluebird Bio expects delay on FDA sickle cell drug application

The goal of submitting lovo-cel for US market clearance by the end of March is beginning to look unobtainable.
By Angelica Peebles, bloomberg

Bluebird Bio Inc. expects to fall short of its goal to seek regulatory approval for its sickle cell gene therapy by the end of March, the latest setback for the struggling biotechnology company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading